Latest News and Press Releases

ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01          EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference         Marseille, France, January 6, 2022 – ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre...

Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...

ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...

ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021         First EVICTION data from checkpoint inhibitor-refractory solid tumor...

ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells First published study showing the role and sequential interaction of...

ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...

ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today...